Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors

Treatment Side Effects Clinical Trial

Official title:

A Clinical Study on Signal Switch Receptor Modified TIL for the Treatment of Advanced Gynecologic Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05098171
• Other study ID #: GC201-1.0
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 26, 2021
• Est. completion date: September 25, 2025

Study information

• Verified date: April 2024
• Source: Shanghai Juncell Therapeutics
• Contact: Clinical GC
• Phone: 086-18001759113
• Email: clinicaltrials[@]juncell.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 25, 2025
• Est. primary completion date: September 25, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age: 18 years to 75 years;

2. Histologically diagnosed as primary/relapsed/metastasized Gynecological tumors;

3. Expected life-span more than 3 months;

4. Karnofsky=60% or ECOG score 0-2;

5. Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.

6. Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;

7. At least 1 evaluable tumor lesion;

8. Hematology and Chemistry(within 7 days prior to enrollment):

• Absolute count of white blood cells=2.5×10^9/L;

• Absolute count of neutropils=1.5×10^9/L;

• Absolute count of lymphocytes =0.7×109/L;

• Platelet count=100×10^9;

• hemoglobin=90 g/L;

• Activated partial thromboplastin time (APTT) =1.5xULN (Unless received anticoagulant therapy within the previous 3 days);

• International normalized ratio (INR) =1.5xULN (Unless received anticoagulant therapy within the previous 3 days);

• Serum creatinine =1.5mg/dL(or =132.6µmol/L), or clearance rate=50mL/min;

• Serum ALT/AST =3×ULN(subjects with liver metastasis =3×ULN);

• Totol bilirubin=1.5×ULN;

9. no absolute or relative contraindications to operation or biopsy;

10. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion;

11. Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;

12. Be able to understand and sign the informed consent document;

13. Be able to stick to follow-up visit plan and other requirements in the agreement.

Exclusion Criteria:

1. Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;

2. Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;

3. Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.

4. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;

5. Severe physical or mental diseases;

6. Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);

7. Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;

8. History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;

9. Having received immunotherapy and developed irAE level greater than Level 3;

10. Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);

11. Females in pregnancy or lactation;

12. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;

13. Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

Related Conditions & MeSH terms

• Effects of Immunotherapy
• Genital Neoplasms, Female
• Treatment Side Effects

Intervention

Biological:
• Signal Switch Receptor Modified TIL
Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.

Locations

Country	Name	City	State
China	Shanghai Tenth People's Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Juncell Therapeutics	Shanghai 10th People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AE)	To characterize the safety profile of Signal Switch Receptor Modified TIL (GC201 TIL) in patients with advanced gynecologic tumors as assessed by incidence of adverse events related to GC201 TIL infusion.	Up to 6 months
Primary	Objective Response Rate (ORR)	Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1): ORR (proportion of patients) = # with CR + # with PR / # with CR + # with PR + # with SD + # with PD.; ( Except baseline evaluation within 28 days before TIL infusion,PET/CT scan will be performed at 6 weeks after GC201 TIL infusion, and than every 6 weeks for 6 months, and then every 6 months after that for up to 3 years)	Up to 36 months
Primary	Disease Control Rate (DCR)	Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1: DCR (proportion of patients) = # with CR + # with PR + # with SD / # with CR + # with PR + # with SD + # with PD.	Up to 36 months
Primary	Duration of Response (DOR)	The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1	Up to 36 months ]
Primary	Progression-Free Survival (PFS)	The time length between GC201 TIL infusion and confirmed subsequent disease progression according to RECIST 1.1	Up to 36 months
Primary	Overall Survival (OS)	The length of time from the date of the start of GC201 TIL treatment that the patients are still alive	Up to 36 months ]
Secondary	Change in Quality of Life	Comparison of patients' quality of life before and after GC201 TIL treatment as assessed by the EORTC QLQ-30 (V3.0).	Up to 36 months